Advertisement

Collaboration › Details
Schrödinger–SVB: investor conference, 202102 supply service Schrödinger presents at SVB Leerink Global Healthcare Conference
![]() |
Period | 2021-02-26 |
![]() |
Partner, 1st | Schrödinger Inc. (Nasdaq: SDGR) |
Group | Schrödinger (Group) | |
Partner, 2nd | SVB Leerink LLC | |
![]() |
Product | SVB Leerink Annual Global Healthcare Conference 2021 DIGITAL |
Product 2 | drug discovery software | |
![]() |
Person | Madden, Jaren (Schrödinger 202011 SVP Investor Relations + Corporate Communications) |
Person 2 | Simon, Stephanie (Ten Bridge Communications 201807) | |
Schrödinger, Inc.. (2/19/21). "Press Release: Schrödinger to Present at the SVB Leerink Partners 10th Annual Global Healthcare Conference". New York, NY.
Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will provide a corporate overview at the SVB Leerink Partners 10th Annual Global Healthcare Conference. The presentation will take place virtually on Friday, February 26, 2021, at 3:00 p.m. ET.
The live webcast can be accessed under "News & Events" in the investors section of Schrödinger’s website and will be archived for approximately 14 days.
About Schrödinger
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages its software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.
Founded in 1990, Schrödinger has over 450 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.
Jaren Irene Madden
Schrödinger, Inc.
jaren.madden@schrodinger.com
617-286-6264
Stephanie Simon (media)
Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333
Record changed: 2021-02-26 |
Advertisement

More documents for Schrödinger (Group)
- [1] Schrödinger, Inc.. (2/19/21). "Press Release: Schrödinger to Present at the SVB Leerink Partners 10th Annual Global Healthcare Conference". New York, NY....
- [2] Schrödinger, Inc.. (11/23/20). "Press Release: Schrödinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb". New York, NY....
- [3] Schrödinger, Inc.. (8/17/20). "Press Release: Schrödinger Announces Closing of Public Offering". New York, NY....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top